Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2001 Apr;56(4):314–316. doi: 10.1136/thorax.56.4.314

Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis

C Haworth 1, P Selby 1, J Adams 1, E Mawer 1, A Horrocks 1, A Webb 1
PMCID: PMC1746027  PMID: 11254825

Abstract

BACKGROUND—Low bone mineral density (BMD) is prevalent in adults with cystic fibrosis. The aim of this study was to assess the effect of intravenous pamidronate on BMD in these subjects.
METHODS—Patients were invited to participate if they had a BMD Z score of -2 or less in the lumbar spine, proximal femur, or distal forearm. Patients were randomised to receive either 30 mg intravenous pamidronate every 3 months + 1 g calcium daily (pamidronate group) or 1 g calcium daily (control group). All pancreatic insufficient patients were prescribed oral vitamin D supplements.
RESULTS—After 6 months of treatment the pamidronate group (n=13) showed a significant increase in absolute BMD compared with the control group (n=15) in the lumbar spine (mean difference 5.8% (CI 2.7% to 8.9%)) and total hip (mean difference 3.0% (CI 0.3% to 5.6%)). However, the pamidronate group showed a reduction in BMD compared with the control group in the distal forearm (mean difference -1.7% (CI -3.7% to 0.3%)). The use of pamidronate was associated with a high incidence of bone pain in non-corticosteroid treated individuals.
CONCLUSION—Intravenous pamidronate increases axial BMD in adults with cystic fibrosis, but the high incidence of bone pain associated with this treatment might limit its use.



Full Text

The Full Text of this article is available as a PDF (102.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson H. R., Butland B. K., Strachan D. P. Trends in prevalence and severity of childhood asthma. BMJ. 1994 Jun 18;308(6944):1600–1604. doi: 10.1136/bmj.308.6944.1600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aris R. M., Lester G. E., Renner J. B., Winders A., Denene Blackwood A., Lark R. K., Ontjes D. A. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):941–946. doi: 10.1164/ajrccm.162.3.2002051. [DOI] [PubMed] [Google Scholar]
  3. Baroncelli G. I., De Luca F., Magazzú G., Arrigo T., Sferlazzas C., Catena C., Bertelloni S., Saggese G. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res. 1997 Mar;41(3):397–403. doi: 10.1203/00006450-199703000-00016. [DOI] [PubMed] [Google Scholar]
  4. Burr M. L., Butland B. K., King S., Vaughan-Williams E. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child. 1989 Oct;64(10):1452–1456. doi: 10.1136/adc.64.10.1452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Conway S. P., Morton A. M., Oldroyd B., Truscott J. G., White H., Smith A. H., Haigh I. Osteoporosis and osteopenia in adults and adolescents with cystic fibrosis: prevalence and associated factors. Thorax. 2000 Sep;55(9):798–804. doi: 10.1136/thorax.55.9.798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Haworth C. S., Selby P. L., Webb A. K., Adams J. E., Freemont T. J. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis. Lancet. 1999 May 29;353(9167):1886–1886. doi: 10.1016/s0140-6736(05)75096-0. [DOI] [PubMed] [Google Scholar]
  7. Haworth C. S., Selby P. L., Webb A. K., Dodd M. E., Musson H., McL Niven R., Economou G., Horrocks A. W., Freemont A. J., Mawer E. B. Low bone mineral density in adults with cystic fibrosis. Thorax. 1999 Nov;54(11):961–967. doi: 10.1136/thx.54.11.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Haworth C. S., Selby P. L., Webb A. K., Mawer E. B., Adams J. E., Freemont T. J. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet. 1998 Nov 28;352(9142):1753–1754. doi: 10.1016/S0140-6736(05)79826-3. [DOI] [PubMed] [Google Scholar]
  9. Haworth C. S., Webb A. K., Egan J. J., Selby P. L., Hasleton P. S., Bishop P. W., Freemont T. J. Bone histomorphometry in adult patients with cystic fibrosis. Chest. 2000 Aug;118(2):434–439. doi: 10.1378/chest.118.2.434. [DOI] [PubMed] [Google Scholar]
  10. Hill R., Williams J., Tattersfield A., Britton J. Change in use of asthma as a diagnostic label for wheezing illness in schoolchildren. BMJ. 1989 Oct 7;299(6704):898–898. doi: 10.1136/bmj.299.6704.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Liberman U. A., Weiss S. R., Bröll J., Minne H. W., Quan H., Bell N. H., Rodriguez-Portales J., Downs R. W., Jr, Dequeker J., Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437–1443. doi: 10.1056/NEJM199511303332201. [DOI] [PubMed] [Google Scholar]
  12. Magnus P., Jaakkola J. J. Secular trend in the occurrence of asthma among children and young adults: critical appraisal of repeated cross sectional surveys. BMJ. 1997 Jun 21;314(7097):1795–1799. doi: 10.1136/bmj.314.7097.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ninan T. K., Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren: evidence from two surveys 25 years apart. BMJ. 1992 Apr 4;304(6831):873–875. doi: 10.1136/bmj.304.6831.873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Omran M., Russell G. Continuing increase in respiratory symptoms and atopy in Aberdeen schoolchildren. BMJ. 1996 Jan 6;312(7022):34–34. doi: 10.1136/bmj.312.7022.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Powell C. V., Primhak R. A. Asthma treatment, perceived respiratory disability, and morbidity. Arch Dis Child. 1995 Mar;72(3):209–213. doi: 10.1136/adc.72.3.209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Powell C. V., White R. D., Primhak R. A. Longitudinal study of free running exercise challenge: reproducibility. Arch Dis Child. 1996 Feb;74(2):108–114. doi: 10.1136/adc.74.2.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Price R. I., Gutteridge D. H., Stuckey B. G., Kent G. N., Retallack R. W., Prince R. L., Bhagat C. I., Johnston C. A., Nicholson G. C., Stewart G. O. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium. J Bone Miner Res. 1993 Feb;8(2):209–217. doi: 10.1002/jbmr.5650080212. [DOI] [PubMed] [Google Scholar]
  18. Stewart G. O., Gutteridge D. H., Price R. I., Ward L., Retallack R. W., Prince R. L., Stuckey B. G., Kent G. N., Bhagat C. I., Dhaliwal S. S. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium. Bone. 1999 Feb;24(2):139–144. doi: 10.1016/s8756-3282(98)00163-x. [DOI] [PubMed] [Google Scholar]
  19. Venn A., Lewis S., Cooper M., Hill J., Britton J. Increasing prevalence of wheeze and asthma in Nottingham primary schoolchildren 1988-1995. Eur Respir J. 1998 Jun;11(6):1324–1328. doi: 10.1183/09031936.98.11061324. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES